Biomolecular Network-based Study of a Parasitic Disease and Therapeutic Drugs
##plugins.themes.bootstrap3.article.main##
Abstract
Computational drug repurposing methods, particularly biomolecular network-based disease-drug-target interaction models, are essential tools for integrating large-scale heterogenous molecular information and revealing functional mechanisms, as well as for main regulatory modules of interactants which can be useful in developing new drugs. In the present study, a drug-centric network for a parasitic disease (Echinococcosis) and therapeutic drugs have been considered. A complex network with more than 12,000 vertices and more than 33,000 edges representing interactions of 84 echinococcosis-related genes with associated proteins was built and analyzed. The networks of disease similarity and drug similarity were constructed based on the complex network. As a result, three drugs (D08356, D00701, and D00506) associated with three candidate diseases through three pathways and a protein complex have been extracted. This effort tries to predict the anti-echinococcosis effects of the drugs’ combinations with benzimidazole.
Download Statistics
Downloads
##plugins.themes.bootstrap3.article.details##
Biomolecular network, disease, drug combination, network analysis
[2] KEGG: Kyoto Encyclopedia of Genes and Genomes.
[3] NCBI - National Library of Medicine.
[4] STITCH: chemical association networks.
[5] Eric Alm and Adam P Arkin. Biological networks. Current opinion in structural biology, 13(2):193–202, 2003.
[6] Gary D Bader and Christopher WV Hogue. An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics, 4(1):1–27, 2003.
[7] Irene V. Bijnsdorp, Elisa Giovannetti, and Godefridus J. Peters. Analysis of Drug Interactions, pages 421–434. Humana Press, Totowa, NJ, 2011.
[8] Aurora S Blucher, Shannon K McWeeney, Lincoln Stein, and Guanming Wu. Visualization of drug target interactions in the contexts of pathways and networks with reactomefiviz. F1000Research, 8, 2019.
[9] Abdul Talib Bon. Determining the size of centrality in social networks.
[10] Enrico Brunetti, Peter Kern, and Dominique Angèle Vuitton. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Tropica, 114(1):1–16, 2010.
[11] Feixiong Cheng, István A Kovács, and Albert-László Barabási. Network-based prediction of drug combinations. Nature communications, 10(1):1–11, 2019.
[12] GeneCards Human Gene Database. GeneCards - Human Genes | Gene Database | Gene Search.
[13] E. Diday and J. C. Simon. Clustering Analysis, pages 47–94. Springer Berlin Heidelberg, Berlin, Heidelberg, 1976.
[14] Joseph El-On. Benzimidazole treatment of cystic echinococcosis. Acta tropica, 85(2):243–252, 2003.
[15] Gihanna Galindez, Julian Matschinske, Tim Daniel Rose, Sepideh Sadegh, Marisol Salgado-Albarrán, Julian Späth, Jan Baumbach, and Josch Konstantin Pauling. Lessons from the covid-19 pandemic for advancing computational drug repurposing strategies. Nature Computational Science, 1(1):33–41, 2021.
[16] Detlef Groth, Stefanie Hartmann, Sebastian Klie, and Joachim Selbig. Principal Components Analysis, pages 527–547. Humana Press, Totowa, NJ, 2013.
[17] Beate Grüner, Petra Kern, Benjamin Mayer, Tilmann Gräter, Andreas Hillenbrand, Thomas EF Barth, Rainer Muche, Doris Henne-Bruns, Wolfgang Kratzer, and Peter Kern. Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in germany. GMS infectious diseases, 5, 2017.
[18] Andrew Hemphill, Britta Stadelmann, Reto Rufener, Markus Spiliotis, Ghalia Boubaker, Joachim Müller, Norbert Müller, Daniela Gorgas, and Bruno Gottstein. Treatment of echinococcosis: albendazole and mebendazole–what else? Parasite, 21, 2014.
[19] Namgil Lee, Hojin Yoo, and Heejung Yang. Cluster analysis of medicinal plants and targets based on multipartite network. Biomolecules, 11(4), 2021.
[20] Elaine L. Leung, Zhi-Wei Cao, Zhi-Hong Jiang, Hua Zhou, and Liang Liu. Network-based drug discovery by integrating systems biology and computational technologies. Briefings in Bioinformatics, 14(4):491–505, 08 2012.
[21] Yongjin Li and Jagdish C Patra. Genome-wide inferring gene–phenotype relationship by walking on the heterogeneous network. Bioinformatics, 26(9):1219–1224, 2010.
[22] Stephani Joy Y Macalino, Vijayakumar Gosu, Sunhye Hong, and Sun Choi. Role of computer-aided drug design in modern drug discovery. Archives of pharmacal research, 38(9):1686–1701, 2015.
[23] Donald P McManus, Wenbao Zhang, Jun Li, and Paul B Bartley. Echinococcosis. The Lancet, 362(9392):1295–1304, 2003.
[24] Pablo Porras Millán. Network analysis of protein interaction data: an introduction. 2017.
[25] Jason Montojo, Khalid Zuberi, Harold Rodriguez, Farzana Kazi, George Wright, Sylva L Donaldson, Quaid Morris, and Gary D Bader. Genemania cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics, 26(22):2927–2928, 2010.
[26] Keiichiro Ono. Cytoscape: An Open Source Platform for Complex Network Analysis and Visualization.
[27] World Health Organization. Echinococcosis. https://www.who.int/en/news-room/fact-sheets/detail/echinococcosis.
[28] Kyungsoo Park. A review of computational drug repurposing. Translational and Clinical Pharmacology, 27(2):59–63, 2019.
[29] Georgios A Pavlopoulos, Maria Secrier, Charalampos N Moschopoulos, Theodoros G Soldatos, Sophia Kossida, Jan Aerts, Reinhard Schneider, and Pantelis G Bagos. Using graph theory to analyze biological networks. BioData mining, 4(1):1–27, 2011.
[30] Victor-Bogdan Popescu, Krishna Kanhaiya, Dumitru Iulian Năstac, Eugen Czeizler, and Ion Petre. Network controllability solutions for computational drug repurposing using genetic algorithms. Scientific reports, 12(1):1–16, 2022.
[31] Victor-Bogdan Popescu, José Ángel Sánchez-Martín, Daniela Schacherer, Sadra Safadoust, Negin Majidi, Andrei Andronescu, Alexandru Nedea, Diana Ion, Eduard Mititelu, Eugen Czeizler, et al. Netcontrol4biomed: a web-based platform for controllability analysis of protein–protein interaction networks. Bioinformatics, 37(21):3976–3978, 2021.
[32] Sudeep Pushpakom, Francesco Iorio, Patrick A Eyers, K Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, Tim Guilliams, Joanna Latimer, Christine McNamee, et al. Drug repurposing: progress, challenges and recommendations. Nature reviews Drug discovery, 18(1):41–58, 2019.
[33] Reto Rufener, Luca Dick, Laura D’Ascoli, Dominic Ritler, Amani Hizem, Timothy NC Wells, Andrew Hemphill, and Britta Lundström-Stadelmann. Repurposing of an old drug: in vitro and in vivo efficacies of buparvaquone against echinococcus multilocularis. International Journal for Parasitology: Drugs and Drug Resistance, 8(3):440–450, 2018.
[34] Philippe Sanseau and Jacob Koehler. Editorial: Computational methods for drug repurposing. Briefings in Bioinformatics, 12(4):301–302, 07 2011.
[35] Jack W Scannell, Alex Blanckley, Helen Boldon, and Brian Warrington. Diagnosing the decline in pharmaceutical r&d efficiency. Nature reviews Drug discovery, 11(3):191–200, 2012.
[36] Gisbert Schneider and Uli Fechner. Computer-based de novo design of drug-like molecules. Nature Reviews Drug Discovery, 4(8):649–663, 2005.
[37] Paul Shannon, Andrew Markiel, Owen Ozier, Nitin S Baliga, Jonathan T Wang, Daniel Ramage, Nada Amin, Benno Schwikowski, and Trey Ideker. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research, 13(11):2498–2504, 2003.
[38] Mar Siles-Lucas, Adriano Casulli, Roberto Cirilli, and David Carmena. Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: compounds and therapeutic targets. PLoS neglected tropical diseases, 12(4):e0006422, 2018.
[39] Nicoleta Siminea, Victor Popescu, Jose Angel Sanchez Martin, Daniela Florea, Georgiana Gavril, Ana-Maria Gheorghe, Corina Iţcuş, Krishna Kanhaiya, Octavian Pacioglu, Laura Ioana Popa, et al. Network analytics for drug repurposing in covid-19. Briefings in bioinformatics, 23(1): bbab490, 2022.
[40] Jianlin Wang, Wenxiu Wang, Chaokun Yan, Junwei Luo, and Ge Zhang. Predicting drug-disease association based on ensemble strategy. Frontiers in Genetics, 12:666575, 2021.
[41] Zikai Wu, Yong Wang, and Luonan Chen. Network-based drug repositioning. Molecular BioSystems, 9(6):1268–1281, 2013.
[42] Wei Zheng, Wei Sun, and Anton Simeonov. Drug repurposing screens and synergistic drug-combinations for infectious diseases. British journal of pharmacology, 175(2):181–191, 2018.
[43] Yadi Zhou, Yuan Hou, Jiayu Shen, Yin Huang, William Martin, and Feixiong Cheng. Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2. Cell discovery, 6(1): 1–18, 2020.
The license term for an open-access journal refers to the duration and conditions under which the published content is made available to the public. Open-access journals often use licenses that permit broad use and distribution of the content. A commonly used license for open-access content is a Creative Commons license.
ICTFocus journal has Open Access to articles published under a license by CC BY (Attribution). This license allows others to copy, distribute, display, and perform the work and derivative works based upon it, but only if they give the author or licensor the credits in the manner specified by these.
The license term is typically indefinite, allowing for the ongoing availability of the content to the public. However, the specific license terms and duration can vary depending on the journal's policies and the type of Creative Commons license used. Always refer to the specific license terms provided by the open-access journal to understand how the content can be used.